Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PRLD |
---|---|---|
09:32 ET | 3852 | 2.21 |
09:34 ET | 300 | 2.1601 |
09:36 ET | 400 | 2.219 |
09:41 ET | 100 | 2.2 |
09:43 ET | 350 | 2.2 |
10:01 ET | 460 | 2.18 |
10:03 ET | 1973 | 2.16 |
10:06 ET | 500 | 2.13 |
10:08 ET | 1418 | 2.15 |
10:10 ET | 851 | 2.13 |
10:14 ET | 10295 | 2.13 |
10:17 ET | 100 | 2.15 |
10:19 ET | 329 | 2.15 |
10:24 ET | 1100 | 2.15 |
10:28 ET | 1190 | 2.145 |
10:32 ET | 100 | 2.13 |
10:35 ET | 100 | 2.14 |
10:37 ET | 300 | 2.14 |
10:39 ET | 3166 | 2.18 |
10:44 ET | 380 | 2.19 |
10:46 ET | 100 | 2.2099 |
10:50 ET | 300 | 2.21 |
10:57 ET | 500 | 2.175 |
11:00 ET | 100 | 2.16 |
11:04 ET | 200 | 2.16 |
11:06 ET | 200 | 2.17 |
11:08 ET | 100 | 2.2 |
11:15 ET | 100 | 2.19 |
11:24 ET | 100 | 2.16 |
11:26 ET | 10715 | 2.15 |
11:29 ET | 735 | 2.1498 |
11:31 ET | 395 | 2.14 |
11:33 ET | 100 | 2.14 |
11:36 ET | 100 | 2.15 |
11:38 ET | 100 | 2.13 |
11:40 ET | 100 | 2.14 |
11:42 ET | 350 | 2.14 |
11:44 ET | 200 | 2.14 |
11:45 ET | 200 | 2.14 |
11:47 ET | 208 | 2.135 |
11:49 ET | 100 | 2.14 |
11:54 ET | 200 | 2.15 |
11:56 ET | 100 | 2.13 |
11:58 ET | 300 | 2.13 |
12:02 ET | 100 | 2.14 |
12:03 ET | 300 | 2.12 |
12:07 ET | 300 | 2.15 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Prelude Therapeutics Inc | 121.1M | -1.2x | --- |
X4 Pharmaceuticals Inc | 120.6M | 7.6x | --- |
Skye Bioscience Inc | 121.7M | -1.1x | --- |
Citius Oncology Inc | 119.8M | 6.4x | --- |
Fractyl Health Inc | 119.6M | -1.8x | --- |
Nuvectis Pharma Inc | 117.7M | -4.9x | --- |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $121.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 55.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.50 |
EPS | $-1.80 |
Book Value | $5.64 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.